{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-000019","form_type":"8-K","ticker":"DWTX","cik":"0001818844","company_name":"Dogwood Therapeutics, Inc.","filed_at":"2024-01-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.670096+00:00","generated_at":"2026-06-07T04:47:25.803407+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Virios Therapeutics: FDA alignment on Phase 3 fibromyalgia and Phase 2 Long-COVID endpoint clarity","bullets":["FDA agreed on Phase 3 program for IMC-1 (famciclovir/celecoxib) for fibromyalgia treatment.","FDA accepted fatigue as primary endpoint and orthostatic intolerance as key secondary for IMC-2 Long-COVID Phase 2 study.","Company provided unrestricted grant to Bateman Horne Center for placebo-controlled study of up to 60 LC patients on IMC-2.","New international patent application filed for IMC-2 as treatment for Long-COVID and fatigue conditions.","Company has capital to support operations into Q4 2024; exploring M&A opportunities."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-000019","json":"https://secwatch.observer/filing/0001558370-24-000019.json","markdown":"https://secwatch.observer/filing/0001558370-24-000019.md","text":"https://secwatch.observer/filing/0001558370-24-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818844/000155837024000019/0001558370-24-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818844/000155837024000019/tmb-20240103x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T04:47:25.803407+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}